Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study

Abstract

Background Some studies previously demonstrated that interleukin-17 (IL-17) involves in pulmonary diseases progression. Nevertheless, the role of IL-17 in community-acquired pneumonia (CAP) remains unknown. This study aims to examine the correlations between serum IL-17 with the severity and prognosis in CAP patients through a prospective cohort study. Methods All 239 CAP patients were recruited. Serum IL-17 was detected by enzyme-linked immunosorbent assay (ELISA). The CAP severity was evaluated through CAP severity scores, including CURB-65, CRB-65, PSI, SMART-COP, CURXO and APACHE II. Results Serum IL-17 was gradually increased consistent with the severity of CAP. Correlative analysis suggested that serum IL-17 was associated with clinical physiologic indicators among CAP patients. Logistic regression indicated that serum IL-17 was positively related to CAP severity scores. Additionally, the prognostic outcomes were tracked among CAP patients. The levels of IL-17 on admission were significantly increased in CAP patients with ICU admission, mechanical ventilation, vasoactive agent, death and longer hospitalization days. Logistic regression analyses revealed serum higher IL-17 on admission elevated the risks of vasoactive agent usage and longer hospital stays in CAP patients. The cut-off concentrations of serum IL-17 for death, ICU admission, mechanical ventilation and ≥ 14 hospital stays were 86.80 ng/mL, 84.92 ng/mL, 84.92 ng/mL and 60.29 ng/mL respectively. Conclusions Serum IL-17 on admission is positively associated with the severity and poor prognosis among CAP patients, revealing that IL-17 may implicate in the pathological process of CAP. Therefore, serum IL-17 may become an effective biomarker for diagnosis, prognosis and therapy for CAP patients.

Role of some interleukins in SARS-CoV-2 severity

“…The results are a significant difference in the levels of IL-17A from a gradual decrease among the different groups, a greater priority than the moderate and severe groups group, and moderate group higher than severe group, this is confirmed by Ghazavi et al, (2021), there are studies that indicated an increase in IL-17A in patients with SARS-CoV-2 [20], but they did not indicate the type of severity such as: [21,22,23].…”

“…Because it is involved in the inflammation that takes place in the airways, the potent pro-inflammatory cytokine known as IL-17A is a crucial factor in the overactivation and the overwhelming inflammatory reaction of the body's defensive system [26]. This is because it plays a role in the inflammation that takes place in the airways, According to Zhou et al, which investigations in particular shown that IL-17A has a driving role in the development include pulmonary hypertension, lung fibrosis, emphysema, acute lung injury, patients diagnosed with ARDS had elevated levels of IL-17A in their serum [27,28].…”

Cross-sectional and longitudinal associations of serum Cysteine-rich 61 with severity and prognosis among community-acquired pneumonia patients in China

“…For studying serum biomarkers, fasting blood specimens from CAP patients were collected before intervention or treatment ( 28 , 29 ). Moreover, demographic information and clinical characteristics were obtained from the electronic medical record system in the hospital ( 30 , 31 ). The severity of CAP was evaluated through CAP severity scores (CURB-65, CRB-65, SMART-COP, PSI, CURXO, and APACHE II) ( 32 , 33 ).…”

Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia

“…Taking KL-6 as an example, the serum was centrifuged to obtain the supernatant and diluted at 1: 100 in bovine serum albumin (BSA) to prepare the testing sample. A commercial enzyme-linked immunosorbent assay (ELISA) kit (Abebio, AE36646HU) was used, and the detailed protocol was as described previously [22,23]. Briefly, the test and standard samples were added to antibody-coated 96-well plates and incubated at 37 °C for 2 h. After washing with PBST, the secondary antibody was added, and then the detection solution was added.…”